SOURCE: BioElectronics Corporation

BioElectronics Corporation

February 11, 2009 08:30 ET

BioElectronics Announces Major Shipments

20,000 Units Being Shipped From Maryland Facility During February

FREDERICK, MD--(Marketwire - February 11, 2009) - BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced significantly accelerating shipments in the first quarter of this year. During the month of February, BioElectronics expects to ship more than 20,000 units to various customers located in five countries.

"We are pleased to inform our investors and the market that shipments of our award winning devices are strongly accelerating in the first quarter. Over the next few weeks we will be shipping just over 20,000 units to our customers, mainly located in Europe and Canada. We have just received an additional 20,000 units from our manufacturer in China and we are preparing to also send these units to our customers over the coming weeks," commented Andrew Whelan, CEO of BioElectronics, Corp. "Our international customers are increasingly accepting our technology and we believe this is a trend that will continue throughout 2009."

About BioElectronics Corporation

BioElectronics Corporation is the maker of the Allay™ Menstrual Pain Therapy, the RecoveryRx™ Therapy, ActiPatch® Therapy, and the HealFast™ Therapy for veterinary applications, (http://www.healfasttherapy.com). ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for about a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective patient friendly method to reduce soft tissue pain and swelling. ActiPatch is approved by Health Canada for the relief of pain in musculoskeletal complaints. The US government's food and drug administration (FDA) has cleared the use of the product for reducing edema (swelling) following blepharoplasty and the European Union has approved the product as a class two pulsed electromagnetic medical device as have numerous other international agencies. http://www.bioelectronicscorp.com

Safe Harbor Statement

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies In light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the company has no control.

Contact Information

  • Media Contact:
    Joe Noel
    Emerging Growth Research LLP
    Voice: 925-922-2560